For decades, pharmaceuticals have operated as functional interventions in a patient’s journey.

A prescription is issued, instructions are followed and outcomes are measured clinically. The relationship is transactional: diagnose; treat; move on.

But that model is breaking down.

Patients are no longer passive participants in their care. Trust in the system is breaking down. They are actively seeking information, experimenting with treatments and, crucially, making decisions outside of clinical advice.

Platforms like TikTok have become informal health advisors, where millions of users share personal protocols, miracle cures and medication hacks. Anecdotal advice spreads faster than peer-reviewed evidence.

From a traditional healthcare perspective, this is concerning. From a consumer behaviour perspective, it is entirely predictable.

Behaviours such as micro-dosing Ozempic signal something deeper than non-compliance, they signal adaptation. Patients are not rejecting medicine; they are trying to make it work for their lives.

The uncomfortable truth for pharma is this: when patients turn to influencers over institutions, it is rarely because they prefer misinformation. It is because they are missing something essential from the system itself. This represents both a risk and a significant opportunity.

Trust in healthcare has traditionally been institutional. It has been built through clinical authority, regulation and evidence. But this has never been transparent to the consumers, and now they want more.

Patients now compare healthcare to every other service they use – retail, fintech, hospitality. They expect clarity, responsiveness, personalisation and ongoing support.

In this context, pharma’s historic distance from the end user becomes a liability. The industry has optimised for safety, efficacy and distribution but not for relationships.

There are exceptions of course. Pfizer’s consumer strategy around Viagra demonstrated that brand, education and direct engagement can drive both uptake and loyalty. But these examples remain the minority.

More recently, Novo Nordisk has invested heavily in patient support ecosystems around GLP-1 therapies such as Wegovy.

Haleon, a spin-out of GSK, is building direct consumer health brands with educational and behavioural components.

Digital health platforms like Hims & Hers Health are redefining the experience by combining prescription access with ongoing support, content and subscription models.

These models move beyond the product itself. They begin to address the surrounding experience. However, most still stop short of delivering what patients are clearly asking for: a structured, adaptive strategy for managing their condition.

This becomes particularly evident in chronic conditions such as diabetes, obesity, depression, endometriosis and chronic pain, where outcomes are not determined by a single intervention but by sustained behavioural and lifestyle change over time.

In these contexts, treatment exists on two planes – short-term interventions (medication, symptom relief, acute care) and long-term outcomes (behaviour change, lifestyle adaptation, prevention).

Pharma has historically excelled at the former. It has largely outsourced the latter.
Patients are told what to take, but not always how to live with their condition in a way that leads to meaningful, sustained improvement.

Guidance around nutrition, movement, stress and adherence is often generic or fragmented, or deprioritised due to time constraints in clinical settings and fear of regulation.

The rapid adoption of GLP-1 therapies provides a glimpse into what comes next. These drugs are clinically effective in driving weight loss, but their long-term success is not pharmacological alone.

Patients must adapt diet, activity and behaviours to sustain outcomes. Without this, discontinuation often leads to regression.

What is emerging around these therapies in the private health sector is telling: companion apps; coaching services; nutrition guidance; behavioural tracking. The race is on. In other words, an ecosystem, not just a product.

Novo Nordisk has begun investing in these supporting layers, but the most aggressive moves are coming from outside traditional pharma.

The commercial implication is significant. The winning model will not be the molecule alone, but the system around it. The provider that helps patients achieve sustained outcomes, not just initial results, will capture long-term value.

Look at start-ups like Aide Health entering the market.

‘Patients are not rejecting medicine, they are trying to make it work for their lives’

With human-centred design.

It starts from a simple premise: design for how people actually behave, not how we would like them to behave. The reality is people are time-poor, behaviour change is difficult to sustain, motivation fluctuates and information overload leads to paralysis.

Telling patients to ‘eat better’ or ‘exercise more’ is not a strategy. It is an aspiration.

What patients need is clarity (what matters most now), prioritisation (what to focus on first), feedback (whether what they are doing is working) and adaptation (how to adjust based on results).

In other words, they need a roadmap that shows where they are, where they are headed and how to get there.

Patients are already generating vast amounts of health data – symptoms, side effects, lifestyle changes and outcomes. Today, much of this data is lost, fragmented across apps or never captured at all.

If integrated responsibly, this data could improve individual patient outcomes through personalisation, generate real-world evidence at scale and inform future treatment development. This requires a shift from designing for patients to designing with them.

Co-designed health plans where patients actively contribute data, feedback and preferences enable systems that evolve in real time.

Advances in AI make it increasingly feasible to translate this data into actionable insights at scale, and pathways to regulatory approval (SAMD) are now achievable in six-month timeframes.

This is not about replacing clinical guidance. It is about extending it, in a way that consumers feel valued. Building trust where there is none.

For pharma, this represents a strategic choice: remain a product provider within a fragmented ecosystem or become an orchestrator of outcomes.

This is not just a patient experience issue. It is a market opportunity. According to McKinsey Health Institute, closing the women’s health gap alone could unlock $1 trillion in global economic value annually by 2040.

This figure is not driven by new drugs alone, but by better outcomes – reducing time spent in poor health, improving productivity and addressing systemic gaps in care.
Women currently spend 25% more of their lives in poor health than men, highlighting both unmet need and underinvestment.

The implication is clear: value will increasingly be created not just through innovation in treatment, but through innovation in delivery, experience and long-term outcomes. In other words, strategy at scale.

This is not just a direct-to-consumer strategy. HCPs are increasingly looking for solutions that help them achieve their targets – fewer hospital readmissions, reduced disease progression, lower reliance on costly procedures, improved long-term patient stability.

Their buying decisions are vested in improved adherence, services that support behaviour change, provide visibility into patient progress and reduce long-term intervention costs.

The pharmaceutical partner that can support these goals through integrated services, not just products, becomes significantly more valuable.

For commercial and digital leaders in pharma, the implications are clear. The competitive advantage is shifting from product efficacy alone to experience and outcomes over time.

This means asking different questions; how do we go beyond prescriptions and information to provide support services that achieve long-term outcomes? How do we build trust in a landscape where alternative sources of information are thriving?
The answer is not more content. It is better-designed systems.

Patients are not missing motivation; they are missing structure outside the GP surgery. They want to feel in control of their health, to understand what is working and to see progress over time.

In the absence of this, they will continue to experiment, sometimes successfully, often not. They are trying to build strategies for their health without the tools, frameworks or feedback loops to do so effectively.

If pharma does not step into this space, others will. 

‘The winning model will not be the molecule alone, but the system around it’